Comparative Efficacy of Novel Non-steroidal Topical Therapies for Atopic Dermatitis: A Systematic Review and Network Meta-analysis.

What was studied

This review compared new non-steroid skin treatments for atopic dermatitis. It was a network meta-analysis of randomized trials. The treatments were difamilast, tapinarof, ruxolitinib and roflumilast. It looked at how fast skin cleared. Time points were weeks 1, 2, 4 and 8. The review included 5843 participants.

What they found

Ruxolitinib had the highest odds of treatment success versus vehicle. This held at weeks 2, 4 and 8. Difamilast showed favourable EASI-75 and EASI-90 responses at week 4. Data for difamilast after week 4 were not available. The abstract gives odds for each time point.

What it means for patients

The authors say efficacy varied across the new topical treatments. They say ruxolitinib had the strongest and most consistent estimates. They say response size and timing remain important points. They say the choice of drug may hinge on these.

Why it is not certain yet

Many comparisons were indirect. They used a vehicle comparator. The treatments were mostly not compared head to head. A review can only be as good as the trials in it.

Source

Comparative Efficacy of Novel Non-steroidal Topical Therapies for Atopic Dermatitis: A Systematic Review and Network Meta-analysis.

We restate facts from the source record in our own words. The original wording belongs to its publisher.